Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company today announced that Xenon’s management team will participate in the following investor conferences:

Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ: XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]

You May Also Be Interested In

• Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
• Buckeye Partners Announces Donald R. Sinclair as Chairman
• RANGEMATE Brings Faster Microwave Meals to Back-to-School Season